CVS Caremark’s Post

Cognivia’s Recent Ebook Highlights a Critical Issue in Pain Management The Placebo Response is a major challenge, but our latest ebook also explores effective strategies to tackle it. 📘 Download the full guide to uncover key insights: https://lnkd.in/ej698gj4

Take a look at the GLP-1 receptor structure, a G-protein coupled receptor (GPCR) that’s revolutionizing treatments for weight loss. Medications like Wegovy and Ozempic are targeting this receptor, and some jaw-dropping projections suggest the GLP-1 drug market could reach $400 billion by 2032! In 2024 alone, the $50 billion GLP-1 market has already outpaced the entire GPCR drug market, which sits at $3 billion (despite over 500 drugs, making up ~30% of all drugs). Who could have predicted GLP-1 would become such a game-changer? #GLP1Receptor #GPCR #WeightLossDrugs #DrugDevelopment #MarketGrowth #PharmaTrends #DrugDiscovery

Thoughts on this? >> 'Unsupported' drug price increases add to US costs, ICER claims >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical

AUGTYRO (repotrectinib) Drug Profile, 2024 P.S. If you like this post please 1) Like it (so I know it's useful) and 2) Repost and share it (so others can see it too)

Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update - CNN: Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update  CNN

Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update - CNN: Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update  CNN

Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update - CNN: Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update  CNN

Thoughts on this? >> 'Unsupported' drug price increases add to US costs, ICER claims >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #productmarketing #pharma

Benzodiazepines, also referred to as “Benzo-Dopes”, are an emerging class of lacing agents that includes prescription drugs like Valium and Xanax. In recent months, more and more drugs have been laced with benzodiazepines, leading to higher overdose rates especially considering that they cause delayed overdose symptoms. Benzodiazepines in the unregulated drug market are extremely hard to detect and current drug-checking technologies like infrared spectroscopy often miss them. That’s why MabLab’s comprehensive test strip, which screens for benzodiazepines in addition to dangerous adulterants like fentanyl and xylazine, will play a crucial role in ensuring the safety of users everywhere. Check out the following article to learn more about the steady rise in “Benzo-Dope”: https://lnkd.in/eYuaP_gX #benzo #accuracy #safety #biotech #awareness #mablab #testing

Thoughts on this? >> Merck stops another Winrevair study early based on positive results from earlier PAH trial >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #pharmaceutical #healthcare